Tag: biomarker-based immunoassays market trends

  • Biomarker-Based Immunoassays Market Growth Forecast: Market Size, Key Trends And Emerging Opportunities Through 2030

    Biomarker-Based Immunoassays Market Growth Forecast: Market Size, Key Trends And Emerging Opportunities Through 2030

    Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.

    Biomarker-Based Immunoassays Market Value Analysis: What Growth Lies Ahead Over The Forecast Period?

    The biomarker-based immunoassays market size has expanded quickly in recent years. Projections indicate it will expand from $6.6 billion in 2025 to $7.37 billion in 2026, with a compound annual growth rate (CAGR) of 11.6%. The historical growth has been driven by several factors, including the increasing prevalence of chronic diseases stimulating demand for early diagnostic testing, the expanding use of enzyme linked immunosorbent assay in clinical laboratories, the broadening of hospital diagnostic infrastructure and laboratory networks, the increasing adoption of antibody based detection techniques in research applications, and the evolution of standardized biomarker identification methods in biomedical research.

    The biomarker-based immunoassays market is poised for significant expansion in the upcoming years. It is projected to reach $11.55 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 11.9%. This anticipated growth can be ascribed to several factors, including the increasing demand for personalized medicine and precision diagnostics, the growing integration of AI and machine learning in biomarker analysis, a wider adoption of multiplex and high-throughput immunoassay technologies, the expansion of point-of-care diagnostic testing into remote healthcare settings, and increased investment in pharmaceutical research and drug discovery applications. Prominent trends expected during this forecast period encompass AI-driven biomarker interpretation and predictive disease modeling for improved diagnostic accuracy, multiplex immunoassay platforms that facilitate the simultaneous detection of multiple biomarkers, cloud-integrated immunoassay systems for centralized management of diagnostic data, laboratory automation and robotic sample processing to enhance high-throughput immunoassay testing, and the emergence of next-generation point-of-care immunoassay devices for rapid clinical diagnostics.

    Get A Free Sample Report With In-Depth Market Insights:

    https://thebusinessresearchcompany.com/sample_request?id=54269245&type=smp&name=Biomarker-Based%20Immunoassays%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

    Biomarker-Based Immunoassays Market Opportunity Drivers: What’s Unlocking New Revenue Potential?

    The escalating frequency of oncology cases is anticipated to boost the expansion of the biomarker-based immunoassays market. Oncology cases involve the manifestation of cancers, which stem from abnormal and uncontrolled cellular proliferation capable of spreading throughout the body. The uptick in oncology cases is primarily attributed to aging demographics, as the probability of developing cancer significantly increases with age, and longer lifespans contribute to a greater number of diagnoses. Biomarker-based immunoassays play a crucial role in managing oncology cases by facilitating prompt identification, accurate observation of disease progression, and informing tailored treatment choices through precise recognition of cancer-specific biomarkers. For instance, data from February 2024 by the World Health Organization, an international organization based in Switzerland focused on global health and public health initiatives, projects over 35 million new cancer cases in 2050, marking a 77% rise from the estimated 20 million cases in 2022. Consequently, the growing prevalence of oncology cases is fueling the growth of the biomarker-based immunoassays market.

    Biomarker-Based Immunoassays Market Segment Analysis And Revenue Potential

    The biomarker-based immunoassays market covered in this report is segmented –

    1) By Product: Consumables, Instruments And Analyzers, Reagents And Kits, Services

    2) By Biomarker Type: Protein Biomarkers, Hormone Biomarkers, Cardiac Biomarkers, Cancer Biomarkers, Infectious Disease Biomarkers, Neurological Biomarkers, Autoimmune Disease Biomarkers

    3) By Technology: Chemiluminescence, Enzyme Linked Immunosorbent Assay, Fluorescence, Multiplex, Radioimmunoassay, Other Technologies

    4) By Application: Oncology Diagnostics, Cardiology Diagnostics, Infectious Disease Testing, Endocrinology Testing, Autoimmune Disease Testing, Neurology Diagnostics, Drug Discovery And Development

    5) By End-User: Clinical Diagnostic Laboratories, Pharmaceutical Research And Development, Contract Research Organizations, Hospitals And Clinics, Academic Research Institutes

    Subsegments:

    1) By Consumables: Pipette Tips, Microplates, Sample Containers, Microcentrifuge Tubes, Reagent Reservoirs, Disposable Pipettes

    2) By Instruments And Analyzers: Enzyme Linked Immunosorbent Assay Analyzers, Chemiluminescence Immunoassay Analyzers, Fluorescence Immunoassay Systems, Multiplex Assay Platforms, Radioimmunoassay Instruments, Automated Immunoassay Analyzers

    3) By Reagents And Kits: Enzyme Linked Immunosorbent Assay Kits, Chemiluminescence Immunoassay Reagents, Fluorescence Immunoassay Reagents, Multiplex Assay Kits, Radioimmunoassay Kits, Controls And Standards

    4) By Services: Assay Development Services, Sample Testing Services, Data Analysis Services, Technical Support Services, Clinical Trial Support Services, Training And Consultation Services

    Biomarker-Based Immunoassays Market Innovation Trends Shaping Future Development

    Leading companies in the biomarker-based immunoassays market are directing their efforts towards developing innovative solutions, such as ultrasensitive immunoassay platforms, to facilitate the early and accurate detection of low-abundance biomarkers. These ultrasensitive immunoassay platforms are advanced diagnostic systems engineered to identify extremely low concentrations of biomarkers with high precision and specificity, which contributes to earlier disease detection, enhanced diagnostic accuracy, and improved monitoring of disease progression compared to conventional assays. For instance, in July 2025, Spear Bio Inc., a US-based biotechnology company, unveiled SPEAR UltraDetect, a next-generation ultrasensitive immunoassay solution crafted to improve biomarker detection in neurodegenerative disease research. The platform leverages proprietary homogeneous assay technology that eliminates the requirement for wash steps, unlike traditional heterogeneous immunoassays, thereby enabling faster and more streamlined workflows. It possesses the capability to detect protein biomarkers at attomolar concentrations using as little as 1 µL of sample, significantly enhancing both sensitivity and efficiency. This solution encompasses assays targeting vital neurological biomarkers including pTau217, pTau231, GFAP, and NfL, supporting early and accurate disease analysis.

    Biomarker-Based Immunoassays Market Top Companies Driving Competitive Growth

    Major companies operating in the biomarker-based immunoassays market are Thermo Fisher Scientific Inc., Abbott Laboratories, Merck KGaA, Eurofins Scientific SE, Bio-Rad Laboratories Inc., QIAGEN N. V., Tecan Trading AG, Autobio Diagnostics Co. Ltd., Promega Corporation, Sekisui Diagnostics LLC, Boditech Med Inc., Dynex Technologies Inc., NanoEntek Inc., J. Mitra & Co. Pvt. Ltd., ALPCO Diagnostics LLC, Micropoint Bioscience Inc., Coris BioConcept, MiCo BioMed Co. Ltd., Abionic SA, ANP Technologies Inc., Axela Inc., Epitope Diagnostics Inc., MedMira Inc., Nanomix Inc.

    View The Full Biomarker-Based Immunoassays Market Report:

    https://thebusinessresearchcompany.com/report/biomarker-based-immunoassays-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

    Biomarker-Based Immunoassays Market Global Footprint: Which Region Leads The Market?

    North America was the largest region in the biomarker-based immunoassays market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biomarker-based immunoassays market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

    Reach Out To Our Team:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas: +1 310-496-7795

    Asia: +44 7882 955267 & +91 8897263534

    Europe: +44 7882 955267

    Email us at: marketing@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Biomarker-Based Immunoassays Market Size Projected To Increase From $7.37 Billion To $11.55 Billion During The Forecast Period

    Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.

    Biomarker-Based Immunoassays Market Forecast Highlighting Growth From $7.37 Billion To $11.55 Billion

    The biomarker-based immunoassays market has experienced considerable expansion in recent years. This market is expected to increase from $6.6 billion in 2025 to $7.37 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 11.6%. The historical growth of this market can be attributed to factors such as the rising incidence of chronic diseases, which has intensified the demand for early diagnostic testing, the expanded application of enzyme linked immunosorbent assay in clinical laboratories, improvements in hospital diagnostic infrastructure and laboratory networks, the increasing use of antibody based detection techniques in research applications, and the formulation of standardized biomarker identification methods in biomedical research.

    The biomarker-based immunoassays market is projected to experience substantial expansion in the coming years, reaching a valuation of $11.55 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 11.9%. This projected growth during the forecast period is fueled by several factors, including the escalating demand for personalized medicine and precise diagnostics, the greater incorporation of AI and machine learning into biomarker analysis, the wider embrace of multiplex and high-throughput immunoassay techniques, the broader deployment of point-of-care diagnostic testing in distant healthcare environments, and increased financial commitments to pharmaceutical research and drug discovery initiatives. Key trends anticipated in this period encompass AI-powered biomarker interpretation alongside predictive disease modeling to improve diagnostic precision, multiplex immunoassay platforms allowing for the concurrent identification of numerous biomarkers, cloud-based immunoassay systems for consolidated management of diagnostic data, laboratory automation combined with robotic sample handling for efficient high-throughput immunoassay analysis, and advanced point-of-care immunoassay devices for swift clinical diagnoses.

    Download A Free Sample Report For Comprehensive Market Insights:

    https://www.thebusinessresearchcompany.com/sample_request?id=11186796&type=smp

    Biomarker-Based Immunoassays Market Growth Factors Supporting Long-Term Expansion

    The escalating number of oncology cases is anticipated to fuel the expansion of the biomarker-based immunoassays market. Oncology cases, defined as the occurrence of cancers stemming from abnormal and uncontrolled cellular growth that can disseminate to various body parts, are on the rise primarily due to aging populations. The risk of developing cancer increases substantially with age, and longer life expectancies lead to a greater number of diagnosed cases. Biomarker-based immunoassays are instrumental in managing oncology cases by enabling early detection, meticulous monitoring of disease progression, and guiding personalized treatment decisions through the accurate identification of cancer-specific biomarkers. For example, in February 2024, the World Health Organization projected over 35 million new cancer cases by 2050, marking a 77% increase from the estimated 20 million cases in 2022. Therefore, the increasing incidence of oncology cases is a significant driver for the growth of the biomarker-based immunoassays market.

    Biomarker-Based Immunoassays Market Categorization By Product Type And Application

    The biomarker-based immunoassays market covered in this report is segmented –

    1) By Product: Consumables, Instruments And Analyzers, Reagents And Kits, Services

    2) By Biomarker Type: Protein Biomarkers, Hormone Biomarkers, Cardiac Biomarkers, Cancer Biomarkers, Infectious Disease Biomarkers, Neurological Biomarkers, Autoimmune Disease Biomarkers

    3) By Technology: Chemiluminescence, Enzyme Linked Immunosorbent Assay, Fluorescence, Multiplex, Radioimmunoassay, Other Technologies

    4) By Application: Oncology Diagnostics, Cardiology Diagnostics, Infectious Disease Testing, Endocrinology Testing, Autoimmune Disease Testing, Neurology Diagnostics, Drug Discovery And Development

    5) By End-User: Clinical Diagnostic Laboratories, Pharmaceutical Research And Development, Contract Research Organizations, Hospitals And Clinics, Academic Research Institutes

    Subsegments:

    1) By Consumables: Pipette Tips, Microplates, Sample Containers, Microcentrifuge Tubes, Reagent Reservoirs, Disposable Pipettes

    2) By Instruments And Analyzers: Enzyme Linked Immunosorbent Assay Analyzers, Chemiluminescence Immunoassay Analyzers, Fluorescence Immunoassay Systems, Multiplex Assay Platforms, Radioimmunoassay Instruments, Automated Immunoassay Analyzers

    3) By Reagents And Kits: Enzyme Linked Immunosorbent Assay Kits, Chemiluminescence Immunoassay Reagents, Fluorescence Immunoassay Reagents, Multiplex Assay Kits, Radioimmunoassay Kits, Controls And Standards

    4) By Services: Assay Development Services, Sample Testing Services, Data Analysis Services, Technical Support Services, Clinical Trial Support Services, Training And Consultation Services

    Biomarker-Based Immunoassays Market Industry Trends Shaping Future Revenue Growth

    Key companies operating within the biomarker-based immunoassays market are prioritizing the development of innovative solutions, such as ultrasensitive immunoassay platforms, to facilitate the early and precise detection of low-abundance biomarkers. These ultrasensitive immunoassay platforms represent advanced diagnostic systems engineered to identify exceptionally low concentrations of biomarkers with high accuracy and specificity, thereby enabling earlier disease detection, enhanced diagnostic precision, and improved monitoring of disease progression compared to traditional assays. For instance, in July 2025, Spear Bio Inc., a US-based biotechnology company, launched SPEAR UltraDetect, a next-generation ultrasensitive immunoassay solution specifically designed to improve biomarker detection in neurodegenerative disease research. This platform employs proprietary homogeneous assay technology that eliminates the need for wash steps, a departure from traditional heterogeneous immunoassays, thus allowing for faster and more streamlined workflows. It possesses the capability to detect protein biomarkers at attomolar concentrations using as little as 1 µL of sample, significantly enhancing sensitivity and efficiency. The solution incorporates assays targeting critical neurological biomarkers including pTau217, pTau231, GFAP, and NfL, which support early and accurate disease analysis.

    Biomarker-Based Immunoassays Market Company Landscape And Strategic Competition

    Major companies operating in the biomarker-based immunoassays market are Thermo Fisher Scientific Inc., Abbott Laboratories, Merck KGaA, Eurofins Scientific SE, Bio-Rad Laboratories Inc., QIAGEN N. V., Tecan Trading AG, Autobio Diagnostics Co. Ltd., Promega Corporation, Sekisui Diagnostics LLC, Boditech Med Inc., Dynex Technologies Inc., NanoEntek Inc., J. Mitra & Co. Pvt. Ltd., ALPCO Diagnostics LLC, Micropoint Bioscience Inc., Coris BioConcept, MiCo BioMed Co. Ltd., Abionic SA, ANP Technologies Inc., Axela Inc., Epitope Diagnostics Inc., MedMira Inc., Nanomix Inc.

    Access The Complete Biomarker-Based Immunoassays Market Report:

    https://www.thebusinessresearchcompany.com/report/biomarker-based-immunoassays-market-report

    Biomarker-Based Immunoassays Market Regional Outlook: Where Are The Largest Opportunities Located?

    North America was the largest region in the biomarker-based immunoassays market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biomarker-based immunoassays market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas: +1 310-496-7795

    Asia: +44 7882 955267 & +91 8897263534

    Europe: +44 7882 955267

    Email us at: marketing@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model